Celularity Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELU research report →
Range $3 – $3
Price Chart
About the company
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases.
- CEO
- Robert Joseph Hariri
- IPO
- 2019
- Employees
- 115
- HQ
- Florham Park, NJ, US
Get TickerSpark's AI analysis on CELU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.23M
- P/E
- -0.63
- Fwd P/E
- 1.18
- PEG
- 0.02
- P/S
- 2.70
- P/B
- -1.46
- EV/EBITDA
- -1.54
- Div Yield
- 0.00%
- Gross Margin
- 79.62%
- Op Margin
- -321.32%
- Net Margin
- -375.77%
- ROE
- 239.78%
- ROIC
- -192.99%
Latest fiscal year · YoY change
- Revenue
- $26.55M-51.0%
- Gross Profit
- $20.19M-48.5%
- Op Income
- $-61,308,000
- Net Income
- $-91,800,000-58.6%
- EPS
- $-3.59-35.7%
- OCF Growth
- -107.1%
- FCF Growth
- -102.0%
- 52W High
- $2.55
- 52W Low
- $0.56
- 50D MA
- $1.14
- 200D MA
- $1.09
- Beta
- 0.54
- RSI (14)
- 67
- Avg Volume
- 3.89M
No earnings-call transcripts are available for CELU yet.
- Free Float
- 65.2%
- Shares Outstanding
- 28.95M
- Float Shares
- 18.87M
of shares held by institutions
38 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| C V Starr & Co Inc | 764.07K | 0 |
| Vanguard Group Inc | 676.65K | 0 |
| Vanguard Capital Management LLC | 621.11K | 0 |
| Geode Capital Management, LLC | 167.15K | ▼ 23.93K |
| Citadel Advisors LLC | 99.05K | ▲ 99.05K |
| Vanguard Fiduciary Trust Co | 79.87K | 0 |
| Blackrock, Inc. | 76.36K | ▼ 51.14K |
| State Street Corp | 57.83K | 0 |
| Hrt Financial LP | 56.59K | ▲ 43.81K |
| Northern Trust Corp | 44.16K | 0 |
| Biltmore Family Office, LLC | 35.00K | 0 |
| Hb Wealth Management, LLC | 31.91K | ▼ 8.50K |
Held by 21 ETFs
Biggest fund positions in CELU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Philip & Daniele Barach Family Trust | other | 2,140,000 |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | other | 192,771 |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | other | 1,457,765 |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | other | 1,457,765 |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | other | 1,177,000 |
| Sep 23, 26 | Barach Daniele Wolf | other | 2,140,000 |
| Sep 23, 26 | Barach Daniele Wolf | other | 192,771 |
| Sep 23, 26 | Barach Daniele Wolf | other | 1,457,765 |
| Sep 23, 26 | Barach Daniele Wolf | other | 1,457,765 |
| Sep 23, 26 | Barach Daniele Wolf | other | 1,177,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CELU coverage
Recent articles, reports, and earnings notes.
No research on CELU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELU report →Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
globenewswire.com · Sep 30
Celularity Announces Naveen Jain to Join Board of Directors
globenewswire.com · Sep 29
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
globenewswire.com · Sep 24
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
gurufocus.com · Aug 27
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
businesswire.com · Aug 27
Celularity Provides Update Regarding Nasdaq Listing Compliance
globenewswire.com · Aug 25
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
globenewswire.com · Jun 4
Celularity Releases CEO Letter to Shareholders
globenewswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.